

Loretta Lazzarato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1005564/publications.pdf>

Version: 2024-02-01

74
papers

2,349
citations

218381

26
h-index

223531

46
g-index

77
all docs

77
docs citations

77
times ranked

3522
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. <i>Journal of Experimental Medicine</i> , 2011, 208, 1949-1962.	4.2	547
2	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. <i>Drug Resistance Updates</i> , 2020, 50, 100682.	6.5	160
3	Antiinflammatory, Gastrosparring, and Antiplatelet Properties of New NO-Donor Esters of Aspirin. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 747-754.	2.9	92
4	A New Class of Ibuprofen Derivatives with Reduced Gastrotoxicity. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3463-3468.	2.9	72
5	Synthesis and biological activity of furoxan derivatives against <i>Mycobacterium tuberculosis</i> . <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 523-531.	2.6	64
6	Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 494-497.	1.3	63
7	Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance. <i>Molecular Pharmaceutics</i> , 2013, 10, 161-174.	2.3	62
8	NO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator Properties. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1449-1457.	2.9	58
9	NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2886-2897.	2.9	46
10	H ₂ S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4881-4889.	2.9	43
11	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8647-8660.	2.9	43
12	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 994-999.	1.3	42
13	Synthesis and antimalarial activities of some furoxan sulfones and related furazans. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 1335-1340.	2.6	41
14	Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution. <i>Pharmaceutics</i> , 2019, 11, 65.	2.0	39
15	Mechanistic Insights into Cyclooxygenase Irreversible Inactivation by Aspirin. <i>ChemMedChem</i> , 2009, 4, 939-945.	1.6	35
16	Searching for New NO-Donor Aspirin-like Molecules: A New Class of Nitrooxy-acyl Derivatives of Salicylic Acid. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1894-1903.	2.9	34
17	The Furoxan System: Design of Selective Nitric Oxide (NO) Donor Inhibitors of COX-2 Endowed with Anti-Aggregatory and Vasodilating Activities. <i>Chemistry and Biodiversity</i> , 2005, 2, 886-900.	1.0	32
18	(Nitrooxyacyloxy)methyl Esters of Aspirin as Novel Nitric Oxide Releasing Aspirins. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5058-5068.	2.9	32

#	ARTICLE	IF	CITATIONS
19	Furazan and furoxan sulfonamides are strong $\hat{\text{I}}\pm$ -carbonic anhydrase inhibitors and potential antiglaucoma agents. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3913-3921.	1.4	32
20	A Nonmetal-Containing Nitric Oxide Donor Activated with Single-Photon Green Light. <i>Chemistry - A European Journal</i> , 2017, 23, 9026-9029.	1.7	32
21	New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5478-5484.	2.9	31
22	Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells. <i>ChemMedChem</i> , 2016, 11, 1371-1379.	1.6	30
23	A novel hybrid aspirin-NO-releasing compound inhibits TNF α release from LPS-activated human monocytes and macrophages. <i>Journal of Inflammation</i> , 2008, 5, 12.	1.5	28
24	Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists and COX-2 Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1647-1660.	1.6	28
25	Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 5852-5860.	1.4	27
26	Doxorubicin-antioxidant co-drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5307-5310.	1.0	27
27	Michael addition of Grignard reagents to tetraethyl ethenylidenebisphosphonate. <i>Journal of Organometallic Chemistry</i> , 2002, 650, 77-83.	0.8	26
28	Fluorescent Nitric Oxide Photodors Based on BODIPY and Rhodamine Antennae. <i>Chemistry - A European Journal</i> , 2019, 25, 11080-11084.	1.7	26
29	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 974-986.	2.9	26
30	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5971-5974.	1.0	25
31	Synthesis of NO-Donor Bisphosphonates and Their in-Vitro Action on Bone Resorption. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1322-1329.	2.9	22
32	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2428-2438.	1.4	22
33	A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-12.	1.9	22
34	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 580.	1.6	22
35	A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light. <i>Bioorganic Chemistry</i> , 2019, 85, 18-22.	2.0	22
36	Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3810-3815.	1.0	21

#	ARTICLE	IF	CITATIONS
37	Water-soluble Nitric Oxide-releasing Acetylsalicylic Acid (ASA) Prodrugs. <i>ChemMedChem</i> , 2013, 8, 1199-1209.	1.6	20
38	Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6729-6738.	2.9	20
39	Furoxan Nitric Oxide Donors Disperse <i>Pseudomonas aeruginosa</i> Biofilms, Accelerate Growth, and Repress Pyoverdine Production. <i>ACS Chemical Biology</i> , 2017, 12, 2097-2106.	1.6	20
40	Multitarget drugs: Focus on the NO-donor hybrid drugs. <i>Pure and Applied Chemistry</i> , 2008, 80, 1693-1701.	0.9	19
41	Enhancing doxorubicin anticancer activity with a novel polymeric platform photoreleasing nitric oxide. <i>Biomaterials Science</i> , 2020, 8, 1329-1344.	2.6	19
42	Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. <i>Chemico-Biological Interactions</i> , 2009, 182, 183-190.	1.7	18
43	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. <i>European Journal of Medicinal Chemistry</i> , 2018, 144, 612-625.	2.6	18
44	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5199-5206.	1.4	16
45	A generator of peroxyxynitrite activatable with red light. <i>Chemical Science</i> , 2021, 12, 4740-4746.	3.7	15
46	Nitrooxymethyl-substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization. <i>Chemistry and Biodiversity</i> , 2009, 6, 369-379.	1.0	14
47	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. <i>Journal of Pineal Research</i> , 2007, 42, 371-385.	3.4	13
48	A Potent and Selective P-gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. <i>ChemMedChem</i> , 2016, 11, 374-376.	1.6	13
49	Galactosylated Pro-drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. <i>Molecular Pharmaceutics</i> , 2018, 15, 21-30.	2.3	12
50	Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. <i>Molecular Pharmaceutics</i> , 2018, 15, 3101-3110.	2.3	12
51	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 841-850.	1.4	11
52	A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery. <i>ChemMedChem</i> , 2018, 13, 87-96.	1.6	11
53	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. <i>Antioxidants</i> , 2019, 8, 531.	2.2	10
54	Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. <i>Molecular Pharmaceutics</i> , 2019, 16, 4181-4189.	2.3	10

#	ARTICLE	IF	CITATIONS
55	New furoxan derivatives for the treatment of ocular hypertension. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 479-483.	1.0	9
56	Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor. <i>ChemMedChem</i> , 2018, 13, 1238-1245.	1.6	9
57	Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4020-4025.	2.9	8
58	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. <i>Bioorganic Chemistry</i> , 2021, 111, 104911.	2.0	8
59	Nitrooxyacyl Derivatives of Salicylic Acid: Aspirin-Like Molecules that Covalently Inactivate Cyclooxygenase-1. <i>ChemMedChem</i> , 2011, 6, 523-530.	1.6	7
60	Anti-Pseudomonas activity of 3-nitro-4-phenylfuroxan. <i>Microbiology (United Kingdom)</i> , 2018, 164, 1557-1566.	0.7	7
61	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. <i>Chirality</i> , 2006, 18, 430-436.	1.3	6
62	Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols. <i>ChemMedChem</i> , 2008, 3, 1443-1448.	1.6	6
63	A Rapid Screening for Cytochrome P450 Catalysis on New Chemical Entities: Cytochrome P450 BM3 and 1,2,5-Oxadiazole Derivatives. <i>Journal of Biomolecular Screening</i> , 2013, 18, 211-218.	2.6	6
64	Can We Exploit β -Lactamases Intrinsic Dynamics for Designing More Effective Inhibitors?. <i>Antibiotics</i> , 2020, 9, 833.	1.5	6
65	Cryo-EM structures of staphylococcal IsdB bound to human hemoglobin reveal the process of heme extraction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2116708119.	3.3	6
66	NO release regulated by doxorubicin as the green light-harvesting antenna. <i>Chemical Communications</i> , 2020, 56, 6332-6335.	2.2	5
67	NO in Viral Infections: Role and Development of Antiviral Therapies. <i>Molecules</i> , 2022, 27, 2337.	1.7	5
68	<i>gem</i> -Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1054-1059.	1.3	4
69	Multitarget Antioxidant NO-Donor Organic Nitrates: A Novel Approach to Overcome Nitrates Tolerance, an Ex Vivo Study. <i>Antioxidants</i> , 2022, 11, 166.	2.2	4
70	Galactosylated Prodrugs: A Strategy to Improve the Profile of Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> , 2022, 15, 552.	1.7	3
71	Amphiphilic NO-Donor Antioxidants. <i>ChemMedChem</i> , 2007, 2, 234-240.	1.6	2
72	DNA-Targeted NO Release Photoregulated by Green Light. <i>Chemistry - A European Journal</i> , 2020, 26, 13627-13633.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Physicochemical profile and in vitro permeation behavior of a new class of non-steroidal anti-inflammatory drug candidates. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 217-221.	1.9	1
74	Development of a New Class of Potential Antiatherosclerosis Agents: NO-Donor Antioxidants.. <i>ChemInform</i> , 2005, 36, no.	0.1	0